Skip to main content
. Author manuscript; available in PMC: 2020 Sep 29.
Published in final edited form as: Gynecol Oncol. 2019 Mar;152(3):445–451. doi: 10.1016/j.ygyno.2018.11.028

Figure 2. Value scorecards for (A) gBRCA and tBRCA mutation cohorts; (B) HRD cohorts; and (C) wBRCA without HRD.

Figure 2.

-gBRCA=germline BRCA mutation cohort; tBRCA=germline- and somatic-BRCA mutation cohort; HRD=homologous recombination deficiency; wBRCA=wild-type BRCA

-Left y-axis represents ASCO NHB scoring, scaled based on the highest observed NHB in our analysis.

-Right y-axis represents ESMO MCBS grade, and is scaled from 1 to 5 based on ESMO’s grading scale of 1 to 5. In our analysis, ‘Form 2b’ has a maximum possible MCBS grade of 4.